Max Josef Kellner
Junior group leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Recent epidemics of influenza, AIDS, SARS, Ebola, Zika, and COVID-19 suggest that RNA viruses will drive future threats. COVID-19 exposed major gaps in monitoring capabilities, leaving lockdowns as the only means to reduce transmission. However, their effectiveness was limited by economic pressures that forced early relaxation. Identification and isolation of cases can protect health systems, inform policy decisions, and support economic stability. Infectious diseases with pre- or asymptomatic transmission necessitate molecular diagnostic testing. Unlike routine clinical diagnostics, outbreak containment requires prioritizing frequent testing and rapid test results over maximal analytical sensitivity. To strengthen monitoring capabilities, we designed a scalable workflow for specimen collection, analysis, and reporting. Rapid implementation was achieved by reallocating nonmedical, nonprofit, molecular biology research infrastructure. Vigilance is crucial, as the robustness of diagnostic assays can be compromised by emerging mutants. We developed software to analyze genomic variation and applied it to 4,295,664 SARS-CoV-2 genomes collected from patients worldwide. To minimize outbreak size, we developed and validated variant-inclusive qPCR assays that target stable regions. Between September 2020 and December 2021, 476,502 specimens from local staff and caregivers were analyzed, 177,756 of which were processed in batches. This after-action report presents a framework grounded in operational objectives, aiming to provide guidance on containing newly emerging infectious diseases.
Year:
2025
A critical bottleneck for equitable access to population-scale molecular diagnostics is the limited availability of rapid, inexpensive point-of-care tests especially in low- and middle-income countries. Here, we developed an open-source Reverse transcription loop-mediated isothermal amplification (RT-LAMP) molecular assay for the detection of respiratory RNA virus infections. It is based on non-proprietary enzymes, namely HIV-1 reverse transcriptase, Bst LF DNA polymerase and UDG BMTU thermolabile uracil DNA glycosylase. Formulated as liquid or lyophilized reaction mixtures, these reagents enable sensitive colorimetric detection of respiratory samples without the need for prior nucleic acid isolation. We evaluated our open-source lyophilized RT-LAMP assay on clinical samples with suspected COVID-19 infection, demonstrating high sensitivity and 100% specificity compared to the gold standard Reverse transcription quantitative polymerase chain reaction ( RT-qPCR ) . Reaction performance was unaffected by prolonged storage of lyophilized reagents at ambient or elevated temperatures. As a proof of concept, we evaluated the robustness and ease-of-use of lyophilized RT-LAMP reaction mixes through independent laboratory testing of COVID-19 samples in Ghana. Overall, our open-source RT-LAMP assay provides a flexible and scalable point-of-care test that can be adapted for rapid detection of various pathogens in resource-limited settings.
Year:
2024
Year:
2023
Collaborators (9)
Lucia L Prieto-Godino
Junior Group Leader
The Francis Crick Institute
Dominik Handler
Staff Scientist
Institute of Molecular Biotechnology
Johannes Zuber
Senior Group Leader
Research Institute of Molecular Pathology
Gavin Y. Oudit
University of Alberta
Andrea Pauli
Senior Group Leader
Research Institute of Molecular Pathology
Luis Menendez Arias
Research Professor
Consejo Superior de Investigaciones Cientificas
Thomas Oliver Auer
Assistant Professor
University of Fribourg
Johanna Trupke
Core Facility Head
-
Josef M. Penninger
The University of British Columbia
Make your next move.
Prepare your application
Review drafts before you send them.